alpha-Dihydroergocriptine
alpha-Dihydroergocriptine Uses, Dosage, Side Effects, Food Interaction and all others data.
Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. Both compounds are hydrogenated ergot derivatives. Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit Ergoloid mesylate
The effect of alpha-dihydroergocryptine in dopamine receptors was tested in PD patients and seem to generate a significant clinical improvement in the tested patients as well as to reduce motor complications and side effects. In long-term clinical trials with Parkinson disease patients, the administration of alpha-dihydroergocryptine and levodopa, the symptoms were reposted to improve or completely vanish in 80% of the tested individuals. All the registered effects of alpha-dihydroergocryptine suggest a potential neuroprotective effect of this drug and some reports have indicated that this activity may be related to the activation of NF-kB. The effect of alpha-dihydroergocryptine in the dopamine D2 receptor also reduces prolactin plasma levels and induce hypotension. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.
| Trade Name | alpha-Dihydroergocriptine |
| Generic | Dihydro-alpha-ergocryptine |
| Dihydro-alpha-ergocryptine Other Names | alpha-Dihydroergocriptine |
| Type | |
| Formula | C32H43N5O5 |
| Weight | Average: 577.726 Monoisotopic: 577.326419505 |
| Protein binding | Alpha-dihydroergocryptine is highly bound to proteins and it has been reported to present a high affinity for intact human platelets. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
alpha-Dihydroergocriptine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.
Alpha-dihydroergocryptine has been studied for the early treatment of Parkinson disease as well as for its use in migraine prophylaxis, treatment of low blood pressure and peripheral vascular disorder. To know more about the ergoloid mesylate mixture and its uses please visit Ergoloid mesylate.
alpha-Dihydroergocriptine is also used to associated treatment for these conditions: Idiopathic Parkinson's Disease, No primary neurologial disease, idiopathic decreased mental activity
How alpha-Dihydroergocriptine works
Alpha-dihydroergocryptine is an established high-affinity ligand to alpha 1 and alpha 2 adrenoreceptors in a number of tissues as well as a dopamine ligand in the brain. It is reported to be a potent agonist of the dopamine D2 receptor and a partial agonist of the dopamine receptors D1 and D3. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate and to know more about the isomer please visit Epicriptine.
Toxicity
Alpha-dihydroergocryptine does not have effect in fertility and it does not present mutagenic potential. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.
Food Interaction
No interactions found.Volume of Distribution
In preclinical studies, the volume of distribution after intravenous or oral administration was registered to be 11.054 L and 218.630 L respectively. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.
Elimination Route
Alpha-dihydroergocryptine is rapidly absorbed but it presents a very low bioavailability as it is part of a first-pass hepatic metabolism and thus less of 5% of the administered dose reaches blood circulation. The peak plasma concentration is attained after 30-120 minutes. The absorption of alpha-dihydroergocryptine is not affected by the co-administration with food. When administered in repeated oral doses the Cmax after 1 hour was registered to be 2157 pg/ml. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.
Half Life
Alpha-dihydroergocryptine has been studied in Parkinson disease models and it has shown a half-life of 12-16 hours. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.
Clearance
In preclinical studies, the clearance rate after intravenous or oral administration was registered to be 1.129 L/h and 25.98 L/h respectively. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.
Elimination Route
Alpha-dihydroergocryptine is eliminated mainly by feces and to present a very low urinary excretion. To know more about the ergoloid mesylate mixture please visit Ergoloid mesylate.
Innovators Monograph
You find simplified version here alpha-Dihydroergocriptine
